Electronic Activity Tracking System (EATs)
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Coronary Heart Disease
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Investigator)Masking Description: The masking will be imposed on the investigator who will be involved with the recruitment of the participant to prevent selection bias. The allocation of the participant to a group will be randomised using computer-generated random numbers by the other investigator who did not involve in recruiting the participant.Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Primary Objective: To determine the exercise capacity among patients with coronary heart disease (CHD) that utilising an electronic activity tracker system (EATs) during the cardiac rehabilitation phase 2 (CRP2). Secondary Objectives: To assess the efficiency of EATs on patient's exercise adherence ...
Primary Objective: To determine the exercise capacity among patients with coronary heart disease (CHD) that utilising an electronic activity tracker system (EATs) during the cardiac rehabilitation phase 2 (CRP2). Secondary Objectives: To assess the efficiency of EATs on patient's exercise adherence and identify the changes on the patient's cardiovascular risk factors, influence by the EATs utilisation. Primary Endpoint: The patient's exercise capacity. Secondary Endpoints: The patient's weekly exercise adherence; and cardiovascular risk factors include the serum lipid, blood pressure, body mass, body mass index (BMI), blood glucose level, and quality of life (QOL). Study Population: Patient with coronary heart disease Phase: 2 Description of Sites/Facilities Enrolling Participants: Patient engagement with the cardiac rehabilitation phase 2 (CRP2) at the University Malaya Medical Centre (UMMC). Description of Study Intervention: This study is a quantitative study consisting of a pilot study (phase 1) and a randomised control trial (phase 2). The present study will be conducting a single-blinded, three-arm, parallel over 8-weeks study period during CRP2. Measurement will be collected at pre- and post-test (8 weeks). Study duration: 24 months Participant Duration: 8 weeks
Tracking Information
- NCT #
- NCT04330560
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Anwar Suhaimi, MBBS University of Malaya Principal Investigator: Wan Ling Lee, PhD University of Malaya Principal Investigator: Sanjay Rampal Lekhraj Rampal, PhD University of Malaya
Get Well Soon